Serum cholesterol reduction with tamoxifen David V. SchapiraNagi B. KumarGary H. Lyman Report Pages: 3 - 7
Nuclear polymorphism — a prognostic parameter to evaluate local recurrence of female breast cancer H. R. RosenM. StiererR. Weber Report Pages: 9 - 13
Tissue polypeptide antigen in tumor cytosol: A new prognostic indicator in primary breast cancer Massimo GionRiccardo MioneGiuliano Bruscagnin Report Pages: 15 - 21
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors G. H. BakkerB. Setyono-HanJ. G. M. Klijn Report Pages: 23 - 32
Hormone dependence of a mouse mammary tumor line inducedin vivo by medroxyprogesterone acetate Edith KordonClaudia LanariChristiane Dosne Pasqualini Report Pages: 33 - 43
Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer S. GundersenS. KvinnslandH. Høst Report Pages: 45 - 50
Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer Paolo PronzatoFulvio BremaRiccardo Rosso Brief communication Pages: 51 - 54
Breast epithelial antigen levels and breast tumor antigen content R. L. CerianiC. Chan Brief communication Pages: 55 - 58
Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas Olli-P. KallioniemiHeikki JoensuuTimo Koivula Brief communication Pages: 59 - 61
Serum placental isoferritin and breast cancer prognosis M. StiererH. R. RosenCh. Moroz Correspondence Pages: 63 - 63
